Grace Therapeutics (GRCE) Change in Accured Expenses (2019 - 2021)

Grace Therapeutics has reported Change in Accured Expenses for 3 years, with the latest figure at -$1.0 million in Q3 2021.

• Quarterly Change in Accured Expenses rose 55.88% year-over-year to -$1.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $9.6 million (up 270.08% YoY) and the FY2022 annual result came in at $2.4 million, down 64.36% from the prior year.
• Change in Accured Expenses retreated to -$1.0 million in Q3 2021 per GRCE's latest filing, from $27000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $12.6 million in Q1 2021 and troughed at -$2.3 million in Q3 2020.
• A 3-year average of $223200.0 and a median of -$1.0 million in 2020 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2020 and 2021: Change in Accured Expenses tumbled 1365.57% in 2020, then jumped 1302.67% in 2021.
• Over 3 years, Change in Accured Expenses stood at -$696000.0 in 2019, then plunged by 187.21% to -$2.0 million in 2020, then soared by 48.17% to -$1.0 million in 2021.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.0 million, $27000.0, and $12.6 million for Q3 2021, Q2 2021, and Q1 2021 respectively.